Mitomycin C, vindesine, and cisplatin in advanced non-small-cell lung cancer. A phase II study.

A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.

Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer.

etoposide in advanced non-small-cell lung cancer.

Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer.

A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer.

Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study.

High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group.

Phase II study of cisplatin continuous infusion plus vindesine in the treatment of non-small-cell lung cancer.

A phase II study of vindesine plus etoposide in metastatic non-small cell lung cancer.

Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.

A randomized prospective study of cisplatin and vinblastine versus cisplatin, vinblastine and mitomycin in advanced non-small cell lung cancer.

Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study.

Phase I study of BW12C in combination with mitomycin C in patients with advanced gastrointestinal cancer.

Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): a phase II study.

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.

Carboplatin and vindesine in advanced non-small cell lung cancer. A feasibility study.

Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.

A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer.

Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer.

The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.

Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer.

II study.

Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study.

A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer.

Suggest Documents

A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.

Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer.

etoposide in advanced non-small-cell lung cancer.

Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer.

A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer.

Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study.

High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group.

Phase II study of cisplatin continuous infusion plus vindesine in the treatment of non-small-cell lung cancer.

A phase II study of vindesine plus etoposide in metastatic non-small cell lung cancer.

Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.

A randomized prospective study of cisplatin and vinblastine versus cisplatin, vinblastine and mitomycin in advanced non-small cell lung cancer.

Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study.

Phase I study of BW12C in combination with mitomycin C in patients with advanced gastrointestinal cancer.

Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): a phase II study.

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.

Carboplatin and vindesine in advanced non-small cell lung cancer. A feasibility study.

Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.

A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer.

Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer.

The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.

Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer.

II study.

Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study.

A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer.

Mitomycin C, vindesine, and cisplatin in advanced non-small-cell lung cancer. A phase II study.

Recommend Documents

Follow Us